Novogen changes name to Kazia Therapeutics


CommSec's Tom Piotrowski talks with Kazia Executive Director and CEO Dr James Garner about our company name change to Kazia Therapeutics.

"We've had great feedback," Dr Garner told Tom. "It was actually something that was suggested by our investors."

Dr Garner also provided a quick update on Kazia’s pipeline, including the Phase I trial of Cantrixil for recurrent ovarian cancer and our upcoming Phase II trial of the brain cancer drug we in-licensed from Genentech, GDC-0084.